Caner Saygin, MD
@canersaygin.bsky.social
Leukemologist at the University of Chicago
Patients with progressive TP53-mutant CH clones progressed to therapy-related ALL or myeloid neoplasms, while stable clones had lower leukemogenic potential. The data suggest that serial monitoring is more informative than cross-sectional assessment of CH in pts receiving MM tx.
July 16, 2025 at 8:11 PM
Patients with progressive TP53-mutant CH clones progressed to therapy-related ALL or myeloid neoplasms, while stable clones had lower leukemogenic potential. The data suggest that serial monitoring is more informative than cross-sectional assessment of CH in pts receiving MM tx.
The meticulous work co-led by Jen Cooperrider and Arda Karaoglu revealed that ongoing lenalidomide maintenance selectively expands TP53-mutant CH clones as opposed to age-related CH (DTA muts).
Discontinuation of lenalidomide led to stability or regression of TP53-mutant CH.
Discontinuation of lenalidomide led to stability or regression of TP53-mutant CH.
July 16, 2025 at 8:11 PM
The meticulous work co-led by Jen Cooperrider and Arda Karaoglu revealed that ongoing lenalidomide maintenance selectively expands TP53-mutant CH clones as opposed to age-related CH (DTA muts).
Discontinuation of lenalidomide led to stability or regression of TP53-mutant CH.
Discontinuation of lenalidomide led to stability or regression of TP53-mutant CH.
We needed a sensitive NGS assay to monitor clones in pts treated with R or KRd maintenance (ATLAS) and in pts who stopped R after MRD negativity (MRD2STOP).
This was achieved in collaboration with @alexbick.bsky.social at Vanderbilt, using their targeted CH panel.
This was achieved in collaboration with @alexbick.bsky.social at Vanderbilt, using their targeted CH panel.
July 16, 2025 at 8:10 PM
We needed a sensitive NGS assay to monitor clones in pts treated with R or KRd maintenance (ATLAS) and in pts who stopped R after MRD negativity (MRD2STOP).
This was achieved in collaboration with @alexbick.bsky.social at Vanderbilt, using their targeted CH panel.
This was achieved in collaboration with @alexbick.bsky.social at Vanderbilt, using their targeted CH panel.
To understand the impact of lenalidomide on evolution of therapy-related CH, we studied prospectively obtained samples from two major MM trials (ATLAS and MRD2STOP), run by
Ben Derman, Andrzej Jakubowiak and Jen Cooperrider.
Ben Derman, Andrzej Jakubowiak and Jen Cooperrider.
July 16, 2025 at 8:09 PM
To understand the impact of lenalidomide on evolution of therapy-related CH, we studied prospectively obtained samples from two major MM trials (ATLAS and MRD2STOP), run by
Ben Derman, Andrzej Jakubowiak and Jen Cooperrider.
Ben Derman, Andrzej Jakubowiak and Jen Cooperrider.
Nice data but OS curves do not seem to have a plateau. They keep going down. I still don`t think CAR-T cures ALL. Unlike allo curves below showing ~1/3 of pts may be cured. www.nature.com/articles/s41...
March 23, 2025 at 6:18 AM
Nice data but OS curves do not seem to have a plateau. They keep going down. I still don`t think CAR-T cures ALL. Unlike allo curves below showing ~1/3 of pts may be cured. www.nature.com/articles/s41...